Italia markets open in 7 hours 25 minutes

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
0,8700-0,4300 (-33,08%)
Alla chiusura: 05:01PM BST
Schermo intero
Chiusura precedente1,3000
Aperto0,8700
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,8700 - 0,8700
Intervallo di 52 settimane0,8700 - 0,8700
Volume1.068
Media VolumeN/D
Capitalizzazione99.014
Beta (5 anni mensile)1,21
Rapporto PE (ttm)N/D
EPS (ttm)-1,6250
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

    Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in JAMA NeurologySafety analysis on bone biomarkers and growth showed no negative effects of vamoroloneRegulatory filings for vamorolone with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are planned to be completed in Q3-2022 and Q4-2022, respectively Pratteln, Switzerland, and Rockville, MD, USA, September

  • GlobeNewswire

    Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

    Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA). This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and exploratory clinical efficacy on motor function outcomes of vam

  • GlobeNewswire

    Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

    Pratteln, Switzerland, June 30, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Annual General Meeting (AGM) held today at the Company’s domicile in Pratteln, Switzerland. In total, 14,118,025 shares equaling 19.2% of the Company’s share capital were represented. Approval of the 2021 Annual Report, results appropriation, allocation of reserves and dischargeThe shareholders endorsed the Annual Report, the ann